FDA Considering New Metrics To Evaluate Advisory Panel Member Conflicts
Executive Summary
In response to concerns about conflicts of interests involving advisory committee members, FDA has started to examine possible metrics to assess panelists' expertise and relationships with regulated companies
You may also be interested in...
FDA Gains No Impartiality Benefit From Conflict-Of-Interest Policy, Advocates Say
Friends of Cancer Research cites an FDA-sponsored study to argue that agency adherence to an advisory committee conflict-of-interest policy that is stricter than required by law does not increase the impartiality of panel members’ recommendations.
FDA Gains No Impartiality Benefit From Conflict-Of-Interest Policy, Advocates Say
Friends of Cancer Research cites an FDA-sponsored study to argue that agency adherence to an advisory committee conflict-of-interest policy that is stricter than required by law does not increase the impartiality of panel members’ recommendations.
Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role
FDA's appointment of a high-profile consumer advocate to an Office of the Commissioner post continues a strategy of bringing some of the most outspoken critics of both the drug industry and its regulatory agency into FDA